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Background: The discovery of a fetal cells transfer to the mother is a phenomenon with multiple implications for
autoimmunity and tolerance. The prevalence and meaning of the feto-maternal microchimerism (MC) in rheumatic
diseases has not been thoroughly investigated. The aim of this study was to analyze the prevalence of fetal MC in patients
with inflammatory rheumatic diseases and to investigate the association of MC with disease onset and current status.
Methods: A total of 142 women who gave birth to at least one male offspring were recruited: 72 women with
rheumatoid arthritis (RA), 16 women with systemic lupus erythematosus (SLE), and 54 healthy women. For the detection
of fetal microchimerism a nested PCR method was used to amplify a Y chromosome specific sequence (TSPY1). For
characterization of disease activity we analyzed autoantibody profiles and X-rays in RA, and in addition complement levels
in SLE respectively.
Results: A significant higher prevalence of fetal MC was found in RA (18%) and SLE (31%) compared to controls
(3.7%) (p = 0.02 and p = 0.006, resp.). The mean age at disease onset was comparable in MC + and MC- RA patients.
Disease onset occurred 18.7 (MC +) and 19.8 (MC-) years post partum of the first son, respectively. The presence of
anti-CCP and RF did not differ significantly, anti-CCP were found in 75% of MC + and 87% of MC- patients, RF in 75%
of both MC + and MC- patients. A slightly higher mean Steinbrocker score in MC + patients was associated with longer
disease duration in MC + compared to MC- RA. In SLE patients the mean age at disease onset was 42.6 years in MC +
and 49.1 years in MC- patients. Disease onset occurred 24.0 and 26.4 years post partum of the first son for MC + and
MC- patients, respectively. The presence of ANA and anti-dsDNA antibodies, C3, C4 and CH50 did not differ significantly.
Conclusion: Our results indicate a higher frequency of long-term male MC in RA and SLE patients compared with
controls without impact on disease onset and status in RA and SLE.
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Rheumatoid arthritis (RA) and systemic lupus erythe-
matosus (SLE) are autoimmune diseases with a higher
prevalence in women than in men (3:1 women vs. men in
RA and 9:1 in SLE, respectively) [1]. The cause and onset
of the diseases still remain unclear. RA and SLE are, once
established, highly affected by pregnancy. Guthrie et al.* Correspondence: m_kekow@hotmail.com
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reproduction in any medium, provided the orreported protective effects of pregnancy for the devel-
opment of RA in women [2]. In this study the risk of
developing RA increased with the number of years after
the birth of the youngest child. These findings, together
with the first description of fetal DNA in pregnant
women [3,4] gave raise to the question of the role of
this chimerism for the development of autoimmune dis-
eases. The presence of very small amounts of cells or
DNA is now called microchimerism (MC), e.g. detect-
able by PCR [5,6]. Recently the fetal DNA became a
focus of interest as a non invasive diagnostic tool forLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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in pregnant women [7,8].
In autoimmune diseases the frequency of MC differs
but studies indicate that the frequency of MC is higher
in women with some autoimmune diseases than in healthy
women [6]. In the field of rheumatic diseases patients with
scleroderma, RA, SLE und Sjögren’s syndrome have been
investigated [9-16]. However, data are inconsistent due to
small numbers of patients, different methodology, and pa-
tient selection.
Prevalence studies in healthy women by our group
found the TSPY1 gene as MC indicator present in about
70% of the women at delivery declining to 4% after a
4 year follow up [17]. This is quite comparable with other
reports [13,18-20]. For the present study we could apply
the detection of a TSPY1 gene sequence on the Y chromo-
some in patients even decades after delivery.
The aim of our study was to evaluate the frequency of
microchimerism in RA and SLE patients and to investi-
gate the effects of fetal microchimerisms on disease on-
set and status. The detection of fetal MC was performed
by nested PCR. Other sources for male DNA were strictly
excluded by questionnaire. Different clinical measures,
X-ray and laboratory parameters were collected from the
patient’s records. The comparison of MC positive and
MC negative RA and SLE patients with healthy controls
revealed a long persistence of MC.
Methods
Patients
All together 142 female subjects were studied: 72 pa-
tients with RA, 16 patients with SLE and 54 healthy con-
trols. All subjects were selected based on the following
criteria: (a) a previous pregnancy with at least one male
offspring, (b) no history of abortion, and (c) no history
of blood transfusions. The patients had to meet the
American College of Rheumatology criteria for RA and
SLE respectively [21,22]. Clinical data on the patients
with RA and SLE were collected from their medical re-
cords including their X-rays, and laboratory results. Spe-
cial family history was obtained by questionnaires. The
subjects were outpatients in one rheumatology centre
(Clinic of Rheumatology, University of Magdeburg).
The study was approved by the local human subjects
committee of the University of Magdeburg (approval
number 133/04), and all patients were asked for written
consent.
For RA patients, the following data were collected:
rheumatoid factor (RF); anti-cyclic citrullinated peptide
antibodies (anti-CCP); and structural damage as defined
by the Steinbrocker score for X-rays of hand and feet
[23,24]. All X-rays were blinded and red separately by
two rheumatologists. RF and anti-CCP were determined
by commercial assays (ABX Pentra RF CP, HORIBA,Germany; and anti-CCP-ELISA, A.Menarini Diagnostics,
Italy, respectively).
In SLE patients, the antinuclear antibodies (ANA), the
dsDNA antibodies (dsDNA Ab), serum C3, C4, and CH50
were analyzed. ANA testing was performed by indirect im-
mune fluorescence, and the determination of dsDNA Ab
by ELISA (all Euroimmun AG, Germany). Determination
of complement factors C3, C4 and CH50 was run using
a turbidimetric method with assays from Biokit, Spain
(C3, C4), and Wako Chemicals, Germany (CH50).
Sample preparation and nested PCR
Genomic DNA from peripheral blood was extracted
using the QIAamp® DNA Blood Midi Kit (QIAGEN,
Germany) according to the manufacturer’s instructions.
Blood samples from a male subject and a nullipara woman
were used as positive and negative controls.
A sequence in the TSPY gene located on the short arm
of the Y-chromosome (encoding the testis specific pro-
tein Y-linked 1, and also known as CT78 and DYS14)
was detected by amplifying genomic DNA in a nested
polymerase chain reaction (PCR). Primers were designed
based on a sequence described by Arnemann et al. [25].
The following primer pairs were used for the first and
second PCR reactions: first PCR: forward: 5´- ATG CGG
CAG AGA AAC CCT TG - 3´; reverse: 5´- TAA GGC
CTC CTG TGT TCA CG - 3´ and second PCR: forward:
5´- CAG AAG CGA GTT CAG AGC AG - 3´; reverse:
5´- TTC TGA GGC TGA CTG CAC TG - 3´.
The first PCR reaction was performed in a total vol-
ume of 50 μl and contained 5 μl genomic DNA at a con-
centration of 80-100 μg/ml, 5 μl 10 fold Taq polymerase
buffer, MgCl2 at a final concentration of 50 mM, 20
pmol of each primer, 4 μl of the dNTP mix (2 mM total)
and 1.5 units of Taq DNA polymerase (Invitrogen, USA).
PCR conditions were as follows; initial denaturation at
94°C for 5 minutes, 35 cycles at 94°C for 60 seconds;
63°C for 60 seconds; and 72°C for 60 seconds; and a
final extension at 72°C for 10 minutes. Two μl of the
reaction mixture of the first reaction containing the
278 bp amplificate were used as template in the second
PCR reaction in a total volume of 20 μl. The second
primer pair was used, beyond that the composition of
the reaction mixture was identical to the first reaction.
The PCR conditions were also similar to the first reaction,
but only 25 cycles were run. The PCR products were sepa-
rated on a 2% agarose gel in 1fold TRIS borate-EDTA
buffer. For sizing the 186 bp product a 100 bp ladder
was used.
Each PCR amplification step included a positive con-
trol (DNA from a male donor, diluted 1:20,000 in water
for molecular biology), and a negative control (DNA-free
water) to detect PCR contamination. All samples were
tested twice.
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sequences in DNA preparations from a mixture of blood
from a male and a female donor at a ratio of 1:40,000. A
reliable detection of male blood in female blood, male
DNA in female DNA and male DNA in Tris-EDTA buf-
fer with a mixture ratio of 1: 40,000 was possible with
the optimized PCR.
Data processing and analysis
For analysis, the software package SPSS was used (V 18.0).
Data are presented as mean, standard error of the mean
(SEM), min-max, and the 95% confidence interval. The
t-test was used to determine the significance of differ-
ences between the means of independent samples. Dif-
ferences in frequencies were analysed by applying the
Fisher’s exact test.
Results
The overall prevalence of fetal MC was 18.1% in RA pa-
tients (mean 37.3 years after the birth of the last son)
and 31.3% in patients with SLE (mean 29.8 years after
the birth of the last son) which is significantly higher as
compared to 3.7% in healthy controls (HC) (p = 0.023
and p = 0.006, resp.) (Table 1).
In healthy controls, the mean age at the birth of the
first son was 25.9 years which is comparable to the RA
and SLE patients. None of our patients or controls had
disabled children.
Rheumatoid arthritis patients
In RA patients the disease onset was 18.7 and 19.8 years
post partum of the first son for MC + and MC- patients,
respectively (Table 2). Patients with two or more sons
had a higher frequency of MC than patients with only one
son without reaching statistical significance (p = 0.218)
(Table 3). The presence and the levels of anti-CCP and RF
did not differ significantly: anti-CCP were found in 75% of
MC+ and 87% of MC- RA patients; RF in 75% of both
MC+ and MC- patients (Table 2).
A slightly higher Steinbrocker score in MC + patients
(3.2 vs. 3.0) was associated with longer disease duration
of about 23 years in MC + RA and 18 years in MC- RA
with no evidence for structural damage due to MC posi-
tivity (Table 2).
The frequency of biological therapies, mostly TNF block-
ing agents, was comparable in both groups (Table 2). MoreTable 1 Overall prevalence of fetal MC (HC = healthy
controls)
RA1 SLE2,3 HC
MC + 13 (18.1%) 5 (31.3%) 2 (3.7%)
MC - 59 (81.9%) 11 (68.7%) 52 (96.3%)
1RA vs. HC: p = 0.023, 2SLE vs. HC: p = 0.006, 3RA vs. SLE: p = 0.303.than 80% of the patients received methotrexate at a dosage
of 15 to 25 mg / week, and took steroids up to 7.5 mg per
day. Due to the limited number of patients, conclusions
may be difficult.
Systemic lupus erythematosus patients
In SLE, the mean age at disease onset was 42.6 years in
MC + and 49.1 years in MC- patients. Disease onset oc-
curred 24.0 and 26.4 years post partum of the first son
for MC + and MC- patients, respectively (Table 4). Thir-
teen out of 16 patients with SLE (81%) have given birth
to only one son. 40% of MC + patients have more than
one son compared to only 9% of MC- patients (Table 3).
The presence of ANA and dsDNA antibodies, and the
lab test results including C3, C4 and CH50 did not differ
significantly (Table 4). In MC + patients sicca symptoms
were found most frequently (80%) followed by arthritis
(60%), central nervous system abnormalities (20%) and
kidney involvement (20%). In contrast, in MC- patients
joints were affected in 70% of the cases followed by skin
(60%), central nervous system (30%) and sicca symp-
toms (20%).
Discussion
Microchimerisms have been investigated for more than
30 years with different methods. With sensitive techniques
such as PCR even very small amounts of male DNA can
be detected in the female organism [26-28]. In the present
study, patients with RA and SLE were tested for the occur-
rence of the TSPY1 gene in the peripheral blood. The
share of women with MC in RA patients was significantly
increased compared to the control group. The prevalence
of a MC in SLE patients was also significantly increased
compared to the control group. Compared with the RA
group, the prevalence is increased in the SLE group, but
does not achieve statistical significance, which may be due
to the limited number of patients.
A comparison of our data on the prevalence of MC
with other reports has limitations. The detection methods
used in each study and the experimental setting differ not-
ably (Table 5) [14,29-37]. In addition, different inclusion
and exclusion criteria (especially the inclusion of blood
transfusions or abortions) can affect the frequency of de-
tected MC. Depending on methods and patients selected,
the prevalence of MC in RA patients can be found be-
tween 18% (Yan et al.) and 42% (Rak et al.) [14,30]. The
study of Yan et al. compared the frequency of MC in 71
patients with RA and 49 healthy controls without analyz-
ing the severity of disease or duration of disease. Women
with a history of abortion were not excluded from the
study. In healthy individuals they found a slightly elevated
frequency of MC (24%) compared to RA patients (18%)
[31]. Studying 25 pregnant RA patients the same group re-
ported a correlation of RA disease activity and fetal DNA
Table 2 Patient characteristics of MC + and MC- RA patients at study entry
MC + RA MC- RA all RA
Mean age at study entry (SEM) 66.0* (2.5) 61.2* (1.4) 61.7 (1.3)
min-max 48-76 41-84 41-84
95% CI of SEM 58.6/68.5 58.3/64.1 59.2/64.3
Mean age at disease onset (SEM) 43.3* (3.2) 43.3* (1.7) 43.3 (1.5)
min-max 24-59 18-72 18-72
95% CI of SEM 36.1/50.4 40.0/46.7 40.4/50.4
Mean duration (years) between birth of first son and disease onset (SEM) 18.7* (2.9) 19.8* (1.5) 19.6 (1.3)
min-max 0-29 0-37 0-37
95% CI of SEM 12.3/25.5 17.0/22.8 12.3/25.5
Mean age at birth of first son (SEM) 25.4* (1.5) 23.4* (0.6) 23.7 (0.6)
min-max 20-35 18-38 18-38
95% CI of SEM 22.0/28.8 22.9/24.6 22.0/28.8
CCP-antibody level n = n = n =
0-25 IU/ml (negative) 3 (25%) 7 (13%) 10 (15%)
26-100 IU/ml (positive) 1 (8%) 9 (17%) 10 (15%)
101-1000 IU/ml (positive) 5 (42%) 23 (43%) 28 (42%)
>1000 IU/ml (positive) 3 (25%) 15 (28%) 18 (27%)
Total CCP-antibody positive 9* (75%) 47* (87%) 56 (84%)
RF level: 0-20 IU/ml (negative) 3 (25%) 13 (24%) 16 (24%)
21-100 IU/ml (positive) 3 (25%) 31 (56%) 34 (51%)
>100 IU/ml (positive) 6 (50%) 11 (20%) 17 (25%)
Total RF positive 9* (75%) 42* (75%) 51 (75%)
Patients treated with ‘Biologicals‘ 10 (77%)* 40 (68%)* 50 (70%)
Steinbrocker score 1 1 (8%) 6 (10%) 7 (10%)
2 2 (15%) 11 (22%) 13 (20%)
3 3 (23%) 16 (30%) 19 (29%)
4 7 (53%) 22 (37%) 29 (41%)
Mean Steinbrocker score 3.23* 3.04* 3.07
*p (MC + vs. MC-) not statistically significant.
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tion of fetal HLA-DRB1 sequences in the maternal blood
for the detection of MC transmitted to the mother [14].
However, blood transfusions and early fetal loss were not
excluded. They speculate that MC may contribute to theTable 3 Number of sons in RA and SLE patients
1 son ≥2 sons
1RA patients MC+ 7 (63.6%) 4 (36.2%)
1RA patients MC- 47 (82.5%) 10 (17.5%)
Total RA patients 54 (79.4%) 14 (20.6%)
2SLE patients MC+ 3 (60%) 2 (40%)
2SLE patients MC- 10 (91%) 1 (9%)
Total SLE patients 13 (81%) 3 (19%)
1RA: number of sons MC + vs. MC-: p = 0.218.
2SLE: number of sons MC + vs. MC-: p = 0.214.risk of an autoimmune disease by providing susceptibility
alleles. Using the disease activity score 28 (DAS28) no cor-
relation with the presence of MC was found [14]. Time
between the last pregnancy and the DNA testing was not
provided making a direct comparison with our data diffi-
cult. Atkins et al. tested tissue from rheumatic nodules of
15 RA patients for male DNA using a PCR for the DYS14
sequence [32]. 74% of the removed rheumatic nodules
from RA patients tested positive for male DNA. They
found no association of MC and joint destruction [32]. Be-
sides peripheral blood and nodules, other tissues were also
investigated for MC. Hromadnikova et al. analyzed syn-
ovial tissue and skin samples of 19 RA patients for the
SRY gene [34]. The patients had a mean age of 55.2 years
and had given birth to at least one son. They compared
the results to samples from RA patients without sons.
The synovial tissue of 5 out of 13 women (38.5%) and 4
Table 4 Patient characteristics of MC + and MC- SLE patients at study entry
MC + SLE MC- SLE all SLE
Mean age (SEM) 51.2* (3.4) 57.1* (3.7) 55.2 (2.7)
min-max 42-58 45-82 42-82
95% CI of SEM 41.6/60.8 48.9/65.5 49.8/60.7
Mean age at disease onset (SEM) 42.6 *(3.8) 49.1* (4.5) 46.9 (3.3)
min-max 35-54 27-75 27-75
95% CI of SEM 32.1/53.1 39.0/59.2 40.0/54.0
Mean age at birth of first son (SEM) 24.0* (2.4) 26.4* (1.6) 24.7 (1.3)
min-max 18-31 22-38 18-38
95% CI of SEM 16.3/31.7 22.7/30.1 22.8/28.7
ANA titer (Median) 1:640 1:640 1:640
(n = 10 MC- n = 4 MC+)
min-max 160-2560 160-2560 160-2560
dsDNA-antibodies present 0 / 3 (0%) 3 / 10 (30%) 3 / 13 (23%)
C3 (g/l) Mean (n = 9 MC-, n = 2 MC+) 1.47 1.28 1.32
min-max 1.45-1.50 0.94-1.55 0.94-1.55
C4 (g/l) Mean (n = 9 MC-, n = 2 MC+) 0.28 0.23 0.24
min-max 0.22-0.35 0.13-0.33 0.13-0.35
CH50 Mean (U/ml) 56.8 51.4 52.3
(n = 9 MC-, n = 2 MC+) min-max 52.7-60.9 42.1-59.1 42.1-60.9
Normal ranges: C3 0.9-1.8 g/l; C4 0.1-0.4 g/l; CH50 23–46 U/ml; ANA: 1:80–1:320 (+ − ++), 1:640–1:1280 (+++), >1:2560 (++++); dsDNA Ab: < 100 RE/ml; *p (MC + vs. MC-)
not statistically significant.
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from patients without male offspring, no male DNA was
found [34].
In SLE patients, varying data for the prevalence of MC
can be found as well. The frequencies range between 0%
found by Miyashita and 50% as described by Mosca
et al. [15,35]. The latter group analyzed blood samples
from 22 SLE patients and 24 healthy controls for the Y
chromosome using a nested PCR method with strict ex-
clusion criteria. For both groups, in 50% of the blood
samples MCs were detected which may be explained by
a broad variation time between last pregnancy and the
time point of DNA testing. They found no differences in
ANA, dsDNA-Ab, and complement levels associated
with or without MC [35].
Besides pregnancy, high rates of abortions in SLE may
be a major source for feto-maternal MC. A meta-analysis
of 11 studies by Khosrotehrani et al. could identify a higher
rate of MC in patients with fetal loss, which was independ-
ent from the number of gestations [38]. Tissue was often
subject for studies of MC in SLE [36,37]. MC was found in
different tissues including kidney, intestine or lung [33].
In our study, patients who had received blood transfu-
sions were excluded. This is because the kinetic of the
removal of foreign cells and DNA is not yet fully under-
stood [39]. In addition, it is unknown whether the bloodtransfusion is from a male or female donor. Even if the
average percentage of male blood donors is known, it is
difficult to calculate its influence on the prevalence of
MC. By excluding RA and SLE patients with blood trans-
fusions in the past more than 50% of the potential candi-
dates for our study were excluded. A reason for this high
number could be a higher frequency in joint replacement
surgery, cardiovascular diseases, and anemia by the disease
itself or due to side effects of drugs. Many of the investi-
gated patients reported blood transfers in conjunction with
gynecological surgery.
Another issue which has to be taken into account is
that all of our RA and SLE patients were treated with
anti-inflammatory and immune modulating medication.
The treatment reduces the progression of the disease and
decreases differences between treated and non-treated pa-
tients. For selecting RA patients, we used a large local data-
base including many patients receiving biological therapies.
Active treatment may have influence on the progression
including structural damage and laboratory parameters but
this may also have impact on the clearance of fetal compo-
nents. For RA we chose two serological parameters which
are associated with a high disease burden and a poor prog-
nosis (RF and anti-CCP). Both antibodies were found to be
positive in a high number of patients, and the absolute
values indicate a more severe disease. This is also reflected
Table 5 Overview of major MC studies in RA and SLE patients










RA 71 RA; 49 HC PCR/ PBMC 18% RA, 24% HC n.r. / 33 (median) n.r. Yan et al. [31]
RA, JIA 25 pregnant patients: PCR/ PBMC n.r. / 33 n.r. Yan at al. [30]
(21 with improvement




RA DRB1*01 MC: PCR/PBMC DRB1*01 MC: n.r./ 57 (RA); included Rak et al. [14]
33 RA, 46 HC RA: 30%, HC: 4% 52 (HC) (17%, HC 13%)
DRB1*04 MC: RA: 40%,




PCR/ tissue 13/15 patients,
14/19 nodules
22.5 / 66 included Atkins et al. [32]
RA QKRAA MC: PCR/ PBMC QKRAA MC n.r. / 51 (RA), n.r. Yan et al. [29]
52 RA, 34 HC RA: 17%, HC: 3% 42 (HC)
QRRAA MC: QRRAA MC:
52 RA, 34 HC RA: 40%, HC: 18%
RA 13 patients (synovial
tissue), 10 patients
(skin fibroblasts)
PCR/tissue 38% 16.4 / 55.5 n.r. Hromadnikova
et al. [34]
40%
SLE 1 patient, 44 samples,
11 female control
subjects
FISH/tissue 100% abnormal tissue,
0% normal tissue;
0/11 controls
1 / 33 n.r. Johnson et al. [33]
SLE 22 patients, 24 HC PCR/whole
blood
SLE: 50% HC: 50% n.r. /44 (SLE),
48 (HC)
excluded Mosca et al. [35]
SLE 49 patients (57 renal
biopsies), 51 HC
samples
FISH/tissue SLE: 55% of patients,
51% of samples HC:
25% of samples
n.r. / 31 (SLE) included (31%) Kremer Hovinga
et al. [37]
SLE 7 patients (48 organ
samples), 34 HC
(146 samples)
FISH/tissue SLE: 100% (50% of
samples), HC: 44%,
(14% of samples)
7 /41 (SLE); 47 (HC) excluded Kremer Hovinga
et al. [36]
n.r.: not reported, FISH: fluorescent in situ hybridization. HC: healthy controls.
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treated patients. Further activity scores like the DAS28
were not applied since they may vary over time. Rak et al.
could not find a correlation between the presence of MC
and the DAS28 in a small cohort of eight women [14].
For SLE, we looked for single organ manifestations re-
lated to the disease. The obtained laboratory data indi-
cate no active disease when the blood was taken for MC
analysis. As mentioned before no relationship between
the course of the disease and the presence of MC could
be detected. Patients with an early stage of disease were
not included in this study, so that it would need fur-
ther investigations including patients with early stages of
disease to show an influence of the MC on the disease
onset. So far outliers in our study were not associated
with MC.
Based on post mortem studies and animal experi-
ments, Kremer Hovinga et al. discussed the role of a MCin patients with SLE in detail [40]. One hypothesis is
that chimeric T-lymphocytes can provoke a graft-vs.-
host reaction; which means that by the recognition of
host cells as foreign, activated chimeric T-helper lym-
phocytes may even stimulate the production of SLE spe-
cific antibodies. Another possible explanation is that the
chimeric cell itself is the target of the host-vs.-graft reac-
tion. Antigens present in maternal tissues will stimulate
the immune system when the removal of chimeric anti-
gens is poor, e.g. caused by impaired CD8 or natural
killer cell function. As in our study, however, a relation-
ship between the presence of chimerism and the clinical
picture of the SLE is lacking. In a third hypothesis au-
thors propose a healing effect of the progenitor chimeric
cells replacing already damaged tissue. A consequence
could be that the new tissue could induce a graft-vs.-
host reaction with further tissue damage. Reviewing
the literature the authors also underline the difficulty of
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of unrecognized miscarriages leading to feto-maternal
transfer of blood. In addition, animal studies are difficult
to transfer into human.
Conclusion
In conclusion our data indicate a long persistence of MC
as a potential marker of pathologic clearance of semi-
allogeneic DNA in rheumatic diseases without effects on
disease onset and status. MC could be an epiphenomenon
of autoimmunity and therapy without having an effect on
the clinical manifestation and the phenotype of RA and
SLE. Long-term randomized controlled trials, even to-
gether with the introduction of new DMARDs, would offer
the possibility to detect the role of MC in autoimmune dis-
eases in more detail.
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